Inclusion body myositis in connective tissue disorders: Case report and review of the literature

Clinical Rheumatology

Volumn 22, Issue 4-5, 2003, Pages 324-328

  Derk, Chris T ^a,b   Vivino, F B ^a   Kenyon, L ^a   Mandel, S ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b Department of Rheumatology ^*  (United States)

Author keywords

Inclusion body myositis; Sj gren's syndrome; Systemic lupus erythematosus

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CELECOXIB; CEVIMELINE; METHOTREXATE; OMEPRAZOLE; PREDNISONE; WARFARIN;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; ELECTRON MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; MEDICAL LITERATURE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

BIOPSY, NEEDLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHOTREXATE; MIDDLE AGED; MYOSITIS, INCLUSION BODY; PREDNISONE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 0345328728     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-003-0715-4     Document Type: Article

References (21)

1. Yunis EJ, Samaha FJ (1971) Inclusion body myositis. Lab Invest 25: 240-248
2. Carpenter S, Karpati G, Heller I et al. (1978) Inclusion body myositis. A distinct variety of idiopathic inflammatory myopathy. Neurology 28: 8-17
3. Eisen A, Berry K, Gibson C (1983) Inclusion body myositis: myopathy or neuropathy? Neurology 33: 1109-1114
4. Griggs RC, Askanas V, DiMauro S et al. (1995) Inclusion body myositis and myopathies. Ann Neurol 38: 705-713
5. Chad D, Good P, Adelman L et al. (1982) Inclusion body myositis associated with Sjögren's syndrome. Arch Neurol 39: 186-188
6. Yood RA, Smith TW (1985) Inclusion body myositis and systemic lupus erythematosus. J Rheumatol 12: 568-570
7. Limaye V, Scott G, Kwiatek R et al. (2000) Inclusion body myositis associated with systemic lupus erythernatosus [letter]. Aust NZ J Med 30: 275-276
8. Riggs JE, Schochet SS, Gutmann L et al. (1984) Inclusion body myositis and chronic immune thrombocytopenia. Arch Neurol 41: 93-95
9. Tome FMS, Fardeau M, Lebon P et al. (1981) Inclusion body myositis. Acta Neuropathol (suppl 7) 287-291
10. Lane RJM, Fulthorpe JJ, Hudgson P (1985) Inclusion body myositis a case with associated collagen vascular disease responding to treatment. J Neurol Neurosurg Psychiatry 48: 270-273
11. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz P (1993) The treatment of inclusion body myositis: a retrospective review and randomized, prospective trial of immunosuppressive therapy. Medicine 72: 225-235
12. Cohen MR, Sulaiman AR, Garancis JC, Wortmann RL (1989) Clinical heterogeneity and treatment response in inclusion body myositis. Arthritis Rheum 32: 734-740
13. Plotz P, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW (1995) Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 122: 715-724
14. Oldfors A, Fyhr I (2001) Inclusion body myositis; genetic factors, aberrant protein expression and autoimmunity. Curr Opin Rheumatol 13: 469-475
15. Chou SM (1967) Myxovirus-like structures in a case of human chronic polymyositis. Science 158: 1453-1455
16. Fox SA, Ward BK, Robbins PD et al. (1996) Inclusion body myositis: investigation of the mumps virus hypothesis by PCR. Muscle Nerve
17. Askonsas V, Engel WK (2001) Inclusion body myositis: newest concepts at pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 60: 1-14
18. Kik CC, Croager EJ, Witt CS et al. (1999) Mapping a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex. Immunogenetics 49: 508-516
19. Engel AG, Arahata K (1986) Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 17: 704-721
20. Emslie-Smith A, Arahata K, Engel AG (1989) Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T-cell mediated cytotoxicity in myopathies. Hum Pathol 20: 224-231
21. De Bleeker JL, Engel AG (1994) Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 53: 369-376